secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcturus Therapeutics Holdings Inc. (ARCT)
CIK:        0001768224
Form:       8-K
Filed at:   2023-09-26T23:59:59+00:00
Accession:  0001193805-23-001328
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcturus extends CF Foundation deal; total funding up to ~$25M for ARCT-032 CF program
--------------------------------------------------------------------------------

- CF Foundation increases financial commitment to ~$25M to advance ARCT-032, an mRNA therapeutic for cystic fibrosis.
- Arcturus to provide $15M in matching funds; royalty rates and caps modified with option to reduce via one-time payment.
- Agreement extends prior program initiated in 2017; Phase 1b study in adults with CF planned imminently.
- ARCT-032 is mutation-agnostic and aims to express functional CFTR protein in the lung, addressing root cause of CF.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768224/000119380523001328/0001193805-23-001328-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768224/000119380523001328/e618944_8k-arct.htm
  HTML page:      https://secwatch.observer/filing/0001193805-23-001328

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer